Strathprints Home | Open Access | Browse | Search | User area | Copyright | Help | Library Home | SUPrimo

Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of leishmania donovani

Carter, K.C. and Mullen, A. and Sundar, S. and Kenney, R.T. (2001) Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of leishmania donovani. Antimicrobial Agents and Chemotherapy, 45 (12). pp. 355-359. ISSN 0066-4804

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

In this study, the in vitro and in vivo efficacies of free sodium stibogluconate (SSG) and a nonionic surfactant vesicular formulation of SSG (SSG-NIV) against a laboratory strain ofLeishmania donovani (MHOM/ET/67:LV82) and different clinical isolates of L. donovani were determined. Treatment with SSG-NIV was more effective against intramacrophage amastigotes than treatment with SSG. In vivo murine studies showed that there was interstrain variability in the infectivity of the different L. donovani strains, with two of the strains (20001 and 20003) giving low parasite burdens. In addition, interstrain variability in the antileishmanial efficacy of SSG in a single dose containing 300 mg of Sb(V)/kg of body weight was observed. This dose of free drug either caused a >97% reduction in liver parasite burdens or had no significant effect on parasite burdens compared with the result with the respective control. In some instances, treatment with this free SSG dose also caused a significant reduction in spleen (strain 20006) or bone marrow (strains 20001 and 20009) parasite burdens. Treatment with SSG-NIV was more effective than that with SSG against all of the strains tested. In SSG-responsive strains, the reduction in liver parasite burdens by SSG-NIV treatment was similar to that caused by free SSG. In SSG-nonresponsive strains, SSG-NIV treatment caused at least a 95% reduction in liver parasite burdens. Overall, these results indicate that the use of a vesicular formulation of SSG is likely to increase its clinical efficacy against visceral leishmaniasis.

Item type: Article
ID code: 37358
Keywords: Leishmania donovani, visceral leishmaniasis, liver parasite burdens, Pharmacy and materia medica, Infectious Diseases, Pharmacology, Pharmacology (medical)
Subjects: Medicine > Pharmacy and materia medica
Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Related URLs:
    Depositing user: Pure Administrator
    Date Deposited: 03 Feb 2012 16:06
    Last modified: 04 Sep 2014 18:52
    URI: http://strathprints.strath.ac.uk/id/eprint/37358

    Actions (login required)

    View Item